Related Experiment Videos
[Primary lung cancer treated with fast neutron]
Gan No Rinsho. Japan Journal of Cancer Clinics
|May 1, 1983
Summary
Fast neutron mixed therapy showed no significant survival difference for lung cancer patients compared to X-ray therapy. However, a trend towards improved 1-year survival was observed in Stage II patients receiving neutron therapy.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Primary lung cancer treatment often involves radiation therapy.
- Mixed therapy combines different radiation modalities to potentially improve outcomes.
- Fast neutron therapy offers different biological effects compared to conventional X-rays.
Purpose of the Study:
- To evaluate the efficacy of fast neutron mixed therapy versus X-ray therapy for primary lung cancer.
- To compare survival rates, tumor regression, and radiation-induced pneumonitis between treatment groups.
- To explore potential improvements in mixed therapy protocols.
Main Methods:
- Forty-nine patients with primary lung cancer received fast neutron mixed therapy (6 MeV).
- A control group received Linac X-ray therapy (10 MV), treated by the same radiotherapist.
- Crude survival rates, tumor regression, and pneumonitis incidence were analyzed.
Main Results:
- No significant difference in crude survival rates between fast neutron and X-ray groups.
- A statistically significant improvement in 1-year survival was noted for Stage II patients in the fast neutron group (p<0.05).
- Radiation pneumonitis and tumor regression were comparable; pneumothorax incidence was slightly higher but not significant in the neutron group.
Conclusions:
- Fast neutron mixed therapy did not demonstrate overall superior survival compared to X-ray therapy for primary lung cancer.
- The observed trend in Stage II patients warrants further investigation.
- Future research will focus on optimizing mixed therapy by reducing the interval between neutron and X-ray irradiation to mitigate X-ray therapy's shoulder effect.